Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
China
· Delayed Price · Currency is CNY 3.590
-0.040 (-1.10%)
Mar 10, 2026, 3:00 PM CST
SHA:600664 Revenue
Harbin Pharmaceutical Group had revenue of 3.90B CNY in the quarter ending September 30, 2025, a decrease of -5.29%. This brings the company's revenue in the last twelve months to 15.94B, down -1.72% year-over-year. In the year 2024, Harbin Pharmaceutical Group had annual revenue of 16.18B with 4.65% growth.
Revenue (ttm)
15.94B
Revenue Growth
-1.72%
P/S Ratio
0.57
Revenue / Employee
1.57M
Employees
10,180
Market Cap
9.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.18B | 719.28M | 4.65% |
| Dec 31, 2023 | 15.46B | 1.65B | 11.93% |
| Dec 31, 2022 | 13.81B | 1.01B | 7.86% |
| Dec 31, 2021 | 12.80B | 2.01B | 18.66% |
| Dec 31, 2020 | 10.79B | -1.04B | -8.76% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tianjin Ringpu Bio-Technology | 3.37B |
| Shenzhen Neptunus Bioengineering | 27.28B |
| PharmaBlock Sciences (Nanjing) | 1.98B |
| Zhejiang Garden Biopharmaceutical | 1.24B |
| Zhejiang Xianju Pharmaceutical | 3.59B |
| KPC Pharmaceuticals,Inc. | 6.58B |
| Hunan Er-Kang Pharmaceutical | 1.29B |
| Shandong Lukang Pharmaceutical | 6.19B |